Navigation Links
Adaptive TCR Changes Name to Adaptive Biotechnologies
Date:1/3/2012

SEATTLE, Jan. 3, 2012 /PRNewswire/ -- Adaptive TCR Corporation, a leading provider of next generation sequencing assays for the adaptive immune system marketed under the brand name immunoSEQ, announced today it has changed its name to Adaptive Biotechnologies Corporation effective immediately.

(Logo:  http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)

The name change reflects the expanded capabilities of the company's original immune profiling business as well as the translation of select research findings from the lab to the clinic.

"Replacing TCR with Biotechnologies better represents the full nature and potential of our products and services," explained Chad Robins, CEO and president of the newly named corporation. "For example, immunoSEQ now offers B-cell receptor sequencing, and we are developing clinical applications for the diagnosis and prognosis of cancer. The name change is simply a natural evolution of our business."

The growth of immunoSEQ

immunoSEQ was launched in 2010 as the first high-throughput sequencing assay to profile the complete repertoire of T-cells in patients with cancer, autoimmune disorders, and infectious diseases.

Over the past year, the capabilities of this proprietary and groundbreaking immune sequencing platform have been expanded to include B-cell receptor sequencing and additional T-cell loci. Sequencing assays for non-human primates, bovine, and swine are also under development.

Expanding into clinical applications

The growing body of immune profiling research that has been generated by hundreds of studies looking at the impact of the immune repertoire on clinical outcome have led to the development of several clinical applications, specifically in oncology.

These clinical applications include monitoring minimal residual disease in blood-based cancers, a more accurate laboratory measurement for immune reconstitution post transplantation, and a direct measurement of tumor infiltrating lymphocytes (TIL) as a prognostic indicator of ovarian cancer.

Further, Adaptive is developing threshold tests to stratify patients in clinical trials, as a predictive measure of response to therapeutics and vaccines.

"immunoSEQ is a rapidly growing platform technology that provides fertile ground to move next generation immune sequencing technology into the clinic," commented Robins. "We are developing assays that use a patient's immune profile to inform treatment decisions."

Adaptive Biotechnologies is building a strong patent portfolio as these first-time discoveries are becoming increasingly defensible with accurate and replicable data.

The company intends to make these tools available to as many researchers and clinicians as possible to ensure that the status of a patient's immune system is taken into consideration at the point-of-care.

"Only with this critical information about the immune microenvironment, can genetic testing of a tumor truly be tailored to the individual," said Adaptive's scientific founder Harlan Robins. "A comprehensive lens of the immune repertoire made available by immunoSEQ may be required for the true potential of personalized medicine to be achieved."

All information about the company can now be found at its new web address: www.adaptivebiotech.com.

About Adaptive Biotechnologies Corporation and immunoSEQ™

Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system's defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

 


'/>"/>
SOURCE Adaptive Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design
2. Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
3. Holon: The Process Adaptive Interoperability Framework
4. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
5. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
6. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
7. Chindex International, Inc. Announces Management Changes
8. New Management Changes Poise USANA for Further Growth
9. Concord Medical Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting, Board and Management Changes
10. Dehaier Medical Announces Changes to Board of Directors
11. Max Healthcare Announces Organizational Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 ... the lift is mounted on wheels, it can be wheeled out of the way and ... fasten to the deck. "We have transformed the feedback from customers into specific enhancements and ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a ... witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation ... educator interacting with countless women who had little knowledge of the female characters portrayed ...
Breaking Medicine News(10 mins):